Dupilumab is a monoclonal antibody against the a subunit of the receptor for interleukin 4 and interleukin 13. It is the first biological drug registered in the world for the treatment of atopic dermatitis. Dupilumab turned out to be a milestone in the treatment of atopic dermatitis and an alternative to standard immunosuppressive drugs. https://parisnaturalfoodes.shop/product-category/athletes-blend-vanilla/
Conjunctivitis as a common adverse effect of dupilumab in atopic dermatitis
Internet 2 minutes ago nlzcobfp4n5chWeb Directory Categories
Web Directory Search
New Site Listings